Ann: Expansion and Acceleration of Clinical Programs, page-14

First 14 Last

Share
Profile

Follow
zecs

863 Posts.

425

27/09/22

13:24

Post #: 63900144
Share

Originally posted by dyeman: ↑

This is interesting. It seems that RCE327 can survive through the gastro-intestinal system to reach the urinary tract.

I recall (from somewhere - can't remember) in discussion about treating heliobacter pylori the question as to whether RCE327 would also kill the good bacteria in the gut biome. The answer was "no" on the basis that the RCE327 would degrade before reaching the lower parts of the digestive tract (e.g. the intestines where water and some dissolved waste are siphoned off into the urinary tract). So it seems that this is not the case - RCE327 can survive through to the intestines otherwise it would not end up in urine. So presumably RCE could take out a fair amount of the naturally occuring gut bacteria as well, which would not be good.

The phase 1 trials got to some pretty massive doses and there don't seem to have been any adverse reactions reported, but certainly something to ponder. Any biological experts here? (I'm certainly not one!).

Expand

The UTI trial is presumably IV route, based on the comments in the ann. So, it won't pass through GI tract.

RCE Price at posting: 69.0¢ Sentiment: Hold Disclosure: Held
17 Upvote

1 Great analysis

Reply

Top Stories

SPN

Sparc opens small-scale green H2 plant in SA, but liquidity dried up

MTS

'Outperforming' Metcash books profits lift – even as illegal tobacco rocks sales

Virgin joins Greatland, VBX Ltd as IPO market heats up ahead of FY26

ASX Market Close: Virgin soars on IPO | June 24, 2025

Listen: HotCopper Wire Podcast 014 – Abu Dhabi wants to buy our 'true' oil and gas gem

First 14 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 29.0¢		Change -0.005(1.69%)		Mkt cap ! $83.62M

Open	High	Low	Value	Volume
29.0¢	30.0¢	28.5¢	$37.25K	127.7K

Buyers (Bids)

No.	Vol.	Price($)
4	161128	28.5¢

Sellers (Offers)

Price($)	Vol.	No.
31.0¢	9666	1

View Market Depth

No.	Vol.	Price($)
4	161128	0.285
10	343798	0.280
4	37019	0.275
4	24814	0.270
1	5000	0.265

Price($)	Vol.	No.
0.310	9666	1
0.330	114230	1
0.350	31739	3
0.375	8002	1
0.380	6820	2

Last trade - 16.10pm 24/06/2025 (20 minute delay)

RCE (ASX) Chart

Ann: Expansion and Acceleration of Clinical Programs, page-14

Sparc opens small-scale green H2 plant in SA, but liquidity dried up

'Outperforming' Metcash books profits lift – even as illegal tobacco rocks sales

Virgin joins Greatland, VBX Ltd as IPO market heats up ahead of FY26

ASX Market Close: Virgin soars on IPO | June 24, 2025

Listen: HotCopper Wire Podcast 014 – Abu Dhabi wants to buy our 'true' oil and gas gem

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Expansion and Acceleration of Clinical Programs, page-14

Top Stories

Sparc opens small-scale green H2 plant in SA, but liquidity dried up

'Outperforming' Metcash books profits lift – even as illegal tobacco rocks sales

Virgin joins Greatland, VBX Ltd as IPO market heats up ahead of FY26

ASX Market Close: Virgin soars on IPO | June 24, 2025

Listen: HotCopper Wire Podcast 014 – Abu Dhabi wants to buy our 'true' oil and gas gem

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News